Helmut Kerschbaumer, CEO and Chairman of the Board
Helmut Kerschbaumer trained in distribution with German C&A and joined the management board of the company (Austria). After 15 years in the retailing industry, Helmut was appointed as Managing Director of Melbrosin International, an international pharmaceutical distributor, which he took over in a management buyout in 2000 and later successfully sold to Bioprogress Plc, UK. Helmut spent 2 years as Director at a UK listed pharmaceutical company. Between 2012 and 2016 Helmut was the CEO of IPMD GmbH and between 2013 and 2017 director and CEO at Uluru Inc., USA
Prof.Dr. Achim Schneeberger, CSO and Director of the Board
Achim Schneeberger holds a MD in Medicine from University Tübingen (Germany). Achim started his medical career at the Medical University of Vienna. He has over 20 years experience in biomedical research and drug development focusing on cancer and chronic diseases. Between 2006 and 2016 Achim was CMO of AFFIRIS and responsible for the clinical development of the company’s vaccine candidates in the indications of Alzheimer’s, Parkinson’s, Multiple System Atrophy (orphan disease) and Atherosclerosis covering a total of 19 clinical trials.
Klaus Kuehne, COO and Director of the Board
Klaus Kuehne, a law school graduate (University of Hamburg), started his career as Consultant at HKM. Klaus has over 20 years experience in the pharmaceutical, nutraceutical and medical device industry. As Managing Director he was heading the Legal, Product Development and PR departments. In 2000 he joined the successful management buyout of Melbrosin and subsequent sale in 2007 to Bioprogress Plc, UK. Klaus was engaged at the UK-listed pharmaceutical company in a executive and director function. Between 2013 and 2017 Klaus was board director at ULURU Inc., USA, responsible for development and commercialization of the Companies products.